Literature DB >> 15905062

High throughput assay for the determination of piperaquine in plasma.

N Lindegårdh1, N J White, N P J Day.   

Abstract

A high throughput assay for the determination of the antimalarial piperaquine in plasma has been developed and validated. The assay utilises 96-wellplate formats throughout the whole procedure, and easily enables a throughput of 192 samples a day using a single LC system. Buffer (pH 2.0; 0.05 M) containing internal standard was added to 0.25 mL plasma in a 96-wellplate (2 mL wells). The samples were extracted on a MPC solid phase extraction deep well 96-wellplate (3M Empore). Piperaquine and internal standard were analysed by liquid chromatography with UV detection on a Chromolith Performance (100 mm x 4.6 mm) column with a mobile phase containing acetonitrile-phosphate buffer (pH 2.5; 0.1 M) (8:92, v/v) at a flow rate of 3.0 mL/min. The within-day precisions for piperaquine were 3.3 and 2.3% at 40 and 1250 ng/mL, respectively. The between-day precisions for piperaquine were 5.8 and 1.3% at 40 and 1250 ng/mL, respectively. The total assay precisions using 29 replicates over 5 days were 6.7, 4.5 and 2.7% at 40, 200 and 1250 ng/mL, respectively. The lower limit of quantification (LLOQ) and the limit of detection (LOD) were 10 and 5 ng/mL, respectively using 0.25 mL plasma. Using 1 mL of plasma, it was possible to decrease LLOQ and LOD to 2.5 and 1.25 ng/mL, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905062     DOI: 10.1016/j.jpba.2005.03.031

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  12 in total

1.  Pitfalls in estimating piperaquine elimination.

Authors:  Joel Tarning; Niklas Lindegårdh; Anna Annerberg; Thida Singtoroj; Nicholas P J Day; Michael Ashton; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.

Authors:  Linda L Kjellin; Grant Dorsey; Philip J Rosenthal; Francesca Aweeka; Liusheng Huang
Journal:  Bioanalysis       Date:  2014       Impact factor: 2.681

3.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

4.  Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.

Authors:  Joel Tarning; Marcus J Rijken; Rose McGready; Aung Pyae Phyo; Warunee Hanpithakpong; Nicholas P J Day; Nicholas J White; François Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

6.  Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.

Authors:  J Tarning; E A Ashley; N Lindegardh; K Stepniewska; L Phaiphun; N P J Day; R McGready; M Ashton; F Nosten; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

7.  Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.

Authors:  Dao Van Hoang Nguyen; Quoc Phuc Nguyen; Ngoa Dang Nguyen; Thuy Thi Thanh Le; The Duy Nguyen; Duy Ngoc Dinh; Thanh Xuan Nguyen; Dai Bui; Marina Chavchich; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

8.  Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Authors:  R N Price; A R Hasugian; A Ratcliff; H Siswantoro; H L E Purba; E Kenangalem; N Lindegardh; P Penttinen; F Laihad; E P Ebsworth; N M Anstey; E Tjitra
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

9.  Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment.

Authors:  Rithea Leang; Walter R J Taylor; Denis Mey Bouth; Lijiang Song; Joel Tarning; Meng Chuor Char; Saorin Kim; Benoit Witkowski; Valentine Duru; Anais Domergue; Nimol Khim; Pascal Ringwald; Didier Menard
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

10.  The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.

Authors:  Nguyen Xuan Thanh; Trieu Nguyen Trung; Nguyen Chinh Phong; Huynh Hong Quang; Bui Dai; G Dennis Shanks; Marina Chavchich; Michael D Edstein
Journal:  Malar J       Date:  2012-06-28       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.